Mandatory HPV vaccination and political debate

JAMA

Volumn 306, Issue 15, 2011, Pages 1699-1700

  Gostin, Lawrence O ^a  

^a GEORGETOWN UNIVERSITY LAW CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

AGE; CANCER RISK; DIZZINESS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; GENDER; GOVERNMENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; INJECTION SITE REACTION; NOTE; PAPILLOMAVIRUS INFECTION; POLITICS; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; SEXUAL BEHAVIOR; SYNCOPE; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; VACCINATION;

EID: 80054749442     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.1525     Document Type: Note

References (10)

1. McGreal C, Sample I. Michele Bachmann HPV row prompts fears for vaccine programme in US. September 14, 2011. http://www.guardian.co.uk/world/2011/sep/ 14/michele-bachmann-hpv-vaccine. Accessed September 27, 2011.
2. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007;297(8):813-819. (Pubitemid 46333946)
3. National Cancer Institute. Cervical cancer. http://www.cancer.gov/ cancertopics/types/cervical. Accessed September 27, 2011.
4. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER; Centers for Disease Control and Prevention; Advisory Committee on Immunization Practices. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1-24.
5. Centers for Disease Control and Prevention. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59(20):626-629.
6. Centers for Disease Control and Prevention. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59(20):630-632.
7. Centers for Disease Control and Prevention. Reports of health concerns following HPV vaccination. August 2011. http://www.cdc.gov/vaccinesafety/ vaccines/hpv/gardasil.html. Accessed September 27, 2011.
8. National Conference of State Legislatures. HPV vaccine: state legislation and statutes. September 2011. http://www.ncsl.org/default.aspx?tabid=14381. Accessed September 27, 2011.
9. Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics. 2005;23(11):1107-1122. (Pubitemid 41633402)
10. Centers for Disease Control and Prevention. National and state vaccination coverage among adolescents aged 13 through 17 years - United States, 2010. MMWR Morb Mortal Wkly Rep. 2011;60(33):1117-1123.